| Provided by – Korea Biotechnology Association
In order to support domestic startups that will lead K-Bio innovation in various ways, the Korea Biotechnology Association will hold the overseas expansion program ‘Open Innovation Challenge’ and the investment attraction briefing session ‘Smart Start’ and ‘Golden Seed Challenge’ from the 25th to the 27th. It is held consecutively.
In particular, in the ‘Open Innovation Challenge’, officials from multinational pharmaceutical companies, and in the ‘Smart Start’ and ‘Golden Seed Challenge’, professional judges related to bio investment will evaluate each company’s presentation on site to help domestic startups advance overseas and attract investment. It is expected to serve as a guide.
PART 1. Overseas expansion support
▲ ‘Open Innovation Challenge’ to establish a bridgehead for domestic companies’ overseas expansion
The Korea Biotechnology Association will hold the ‘Open Innovation Challenge’ at the Korea-German Chamber of Commerce and Industry from the 26th to the 27th of this month to connect the open innovation demands of domestic startups with promising biotechnology and multinational pharmaceutical companies seeking to discover new growth engines.
This event is one of the ‘Global Mingle’ programs that support domestic companies’ overseas expansion. Following Bayer AG in April, this event will be held with German multinational pharmaceutical company Boehringer Ingelheim this month.
At this event, 11 companies with less than 7 years of founding and 4 officials, including Weiyi Zhang, CEO of China External Innovation Hub, which is in charge of research and business development in China and venture funds in the Asian region, participated to discuss the possibility of cooperation with Boehringer Ingelheim. is explored in a variety of ways.
On the 26th, ‘Argenomics’, which researches RNA gene therapy, ‘S&K Therapeutics’, which develops treatments for rare immune diseases, ‘Autotech Bio’, which has protein target degradation platform technology, and ‘Lycene’, which develops anti-cancer drugs using bacteriophages. Tech meets with Boehringer Ingelheim officials. ‘Party Appgen’, a new antibody drug and cell therapy research company, ‘Virocure’, an anti-cancer virus new drug development company, ‘ENCell’, a stem cell treatment development company, and ‘GD Biotechnology’, a mitophagy-based treatment development company, also targeted business officials. Make a presentation.
The following day, ‘Aptis’, which is targeting the global pharmaceutical market with its ADC platform technology, ‘Selexin’, which develops anti-cancer immunotherapy drugs, and ‘G Biologics’, which researches autoimmune diseases and anti-cancer drugs, will explore future cooperation plans.
After the company presentation, Boehringer Ingelheim officials deliver to each company the evaluation in five categories, including ▲planning ability, ▲presentation ability, ▲technical originality and implementation ability, ▲competitiveness, and ▲marketability, to help participating companies clearly set the direction for overseas expansion. It is expected that it will help.
PART 2. IR support at each stage of corporate growth
▲ ‘Smart Start’ that will give wings to the growth and leap forward of promising bio companies
In order to support the sustainable and stable growth of excellent bio ventures, the Korea Biotechnology Association, together with KDB Bank and the New Industry Investment Organization Council, held the ‘9th Smart Start’ for domestic companies in the Series B, C and pre-listing stages. held on the 1st.
‘Smart Start’ is an event designed to publicize the company’s value to domestic and foreign investors and provide opportunities to attract investment through the IR of domestic companies with promising biotechnology. IR presentations by six companies that passed a rigorous document screening unfolds.
‘Heim Biotech’, a company specializing in genetic analysis and molecular diagnosis technology, ‘Acesso Biopharma’, a small molecule-based next-generation immunotherapy drug development company, and ‘Avidnet’, an innovative healthcare company based on big data, are making presentations, based on genetic testing. Precision medicine startup ‘SPMED’, exosome new drug development company ‘Brexogen’, and needle-free laser blood collection technology and professional medical laser development company ‘Rameditech’ are also scrambling to attract investment. After the presentation, investment reviewers from Korea Investment Partners, Sunup Investment, and Withwin Investment will provide sharp questions, evaluations, and generous advice for improvement from an investor’s perspective.
In addition, a presentation on 『Bio company growth strategy through KOSDAQ KONEX market IPO』 by a representative of the KOSDAQ Growth Headquarters of the Korea Exchange and a presentation on 『Bio/Healthcare Global Investment Trends』 by a professional reviewer of Korea Investment Partners are also scheduled to be held for companies planning to be listed or enter overseas markets. It is expected to be of great help to domestic companies.
Anyone can watch this event from 2pm on the 25th through the KDB Korea Development Bank YouTube channel or the Next Round online platform.
▲ ‘Golden Seed Challenge’, which discovers hidden gemstones. ‘Golden Seed Challenge’, an investment attraction IR event targeting early bio startups in the pre-A and series A stages, will also be introduced on the 27th.
This event is an IR program aimed at discovering early-stage startups and connecting them with their first investments. The event includes ‘Dr. I&B’, a photodynamic therapy (PDT) technology research and development company, ‘G Biologics’, an autoimmune disease and anticancer drug research and development company, and Brain. ·Five promising startups, including ‘Neurovis’, a central nervous system treatment research and development company, ‘Ingenium Therapeutics’, an immune cell therapy specialist, and ‘Pense’, a bio-printing technology specialist, will introduce their companies.
After IR pitching for each company, investment reviewers from ES Investor, Atinum Investment, Kolon Investment, and K Clavis will provide mentoring and information on difficulties in attracting investment that may be experienced in the early stages of starting a business.
Oh Ki-hwan, executive director of the Korea Biotechnology Association, said, “The demand for overseas venture capital investment (in our companies) and the demand for open innovation cooperation from multinational pharmaceutical companies are gradually increasing, and the number of companies advancing overseas is also rapidly increasing.” “In the future, the association will hold various support programs in the entire cycle of entrepreneurship, growth, development, and reinvestment to provide a foundation for domestic startups to take a leap forward at home and abroad,” he said.
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asia Innovation Hub Pangyo Techno Valley 2021’ news